In conclusion, the inhibition of the CXCL8-CXCR1/2 axis represents a promising therapeutic approach which, either as monotherapy or an adjunctive therapy, may lead to the prevention or reversal of T1D, with a meaningful potential clinical advantage conveyed by its role in multiple components of the disease pathology and its involvement in secondary diabetic complications. This evidence concerns the gene CXCR1 and type 1 diabetes mellitus.